O Bratt

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. ncbi request reprint Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor
    O Bratt
    Department of Urology, Lund University Hospital, Sweden
    Eur Urol 34:19-24. 1998
  2. ncbi request reprint Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study
    O Bratt
    Department of Urology, Lund University Hospital, Sweden
    Eur J Cancer 35:272-7. 1999
  3. ncbi request reprint Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer
    O Bratt
    Department of Urology, University of Lund, Sweden
    Eur J Cancer 36:235-41. 2000
  4. pmc CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
    O Bratt
    Department of Urology, University of Lund, Sweden
    Br J Cancer 81:672-6. 1999
  5. ncbi request reprint Hereditary prostate cancer: clinical characteristics and survival
    O Bratt
    Unit for Urology, Helsingborg Hospital, Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
    J Urol 167:2423-6. 2002
  6. pmc Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
    O Bratt
    Department of Urology, Helsingborg Hospital, Lund University, SE 25187 Helsingborg, Sweden
    Br J Cancer 101:1233-40. 2009

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor
    O Bratt
    Department of Urology, Lund University Hospital, Sweden
    Eur Urol 34:19-24. 1998
    ..The aim of this study was to describe the clinical characteristics of early onset prostate cancer, with special reference to family history as a possible prognostic factor...
  2. ncbi request reprint Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study
    O Bratt
    Department of Urology, Lund University Hospital, Sweden
    Eur J Cancer 35:272-7. 1999
    ..Furthermore, we found self-reported family history of prostate cancer to be a valid estimate of the true incidence of prostate cancer in fathers and brothers of men with prostate cancer...
  3. ncbi request reprint Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer
    O Bratt
    Department of Urology, University of Lund, Sweden
    Eur J Cancer 36:235-41. 2000
    ..The present study underlines the importance of giving thorough, repeated information to men at high risk of prostate cancer...
  4. pmc CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
    O Bratt
    Department of Urology, University of Lund, Sweden
    Br J Cancer 81:672-6. 1999
    ..An association between long CAG repeats and good response to endocrine therapy was also found, but the mechanism and clinical relevance are unclear...
  5. ncbi request reprint Hereditary prostate cancer: clinical characteristics and survival
    O Bratt
    Unit for Urology, Helsingborg Hospital, Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
    J Urol 167:2423-6. 2002
    ..Hereditary prostate cancer accounts for 5% to 10% of all prostate cancer cases. We assessed clinical characteristics and survival in patients with hereditary prostate cancer..
  6. pmc Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
    O Bratt
    Department of Urology, Helsingborg Hospital, Lund University, SE 25187 Helsingborg, Sweden
    Br J Cancer 101:1233-40. 2009
    ..Two open-label phase I clinical trials in patients were conducted to evaluate the safety and tolerability of tasquinimod, with additional pharmacokinetic and efficacy assessments...